Want to see IN:AGARWALEYE full AI Analyst Report?
AGARWALEYE Stock Chart & Stats
₹500.00
--
Market closed
₹500.00
--
Day’s Range― - ―
52-Week Range₹402.10 - ₹567.80
Previous CloseN/A
VolumeN/A
Average Volume (3M)13.83K
Market Cap
₹157.97B
Enterprise Value₹138.83K
Total Cash (Recent Filing)₹2.84B
Total Debt (Recent Filing)₹0.00
Price to Earnings (P/E)105.9
Beta0.65
Next Earnings
Oct 29, 2026EPS Estimate
1.3Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)4.69
Shares Outstanding317,026,180
10 Day Avg. Volume7,500
30 Day Avg. Volume13,832
Financial Highlights & Ratios
PEG Ratio1.92
Price to Book (P/B)6.35
Price to Sales (P/S)6.18
P/FCF Ratio188.09
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)5.81
Revenue Forecast (FY)₹25.49B
Bulls Say, Bears Say
Bulls Say
Strong Revenue ScalingSustained revenue expansion indicates increasing patient demand and successful scaling of the hospital and clinic network. Continued growth can improve infrastructure utilization, strengthen brand reach, and support operating leverage over the next several years.
Improving Operating Cash FlowThe rebound in operating cash generation improves the company’s ability to fund clinical expansion and routine investment internally. Cash flow exceeding net income also suggests that reported profits are currently supported by business operations.
Material Leverage ImprovementA substantially lower debt-to-equity ratio provides greater financial flexibility and reduces balance-sheet risk compared with prior years. The stronger equity base should improve resilience while the company continues expanding its care network.
Bears Say
Gross Margin VolatilitySharp gross-margin compression signals uncertainty around procedure mix, pricing, staffing, or treatment costs. If persistent, it could limit the benefit of revenue growth and make earnings quality less predictable across the company’s network.
Weak Free Cash Flow ConversionThin and uneven free-cash-flow conversion means accounting profits are not consistently translating into discretionary cash. This may constrain internally funded expansion and increase reliance on financing when capital needs rise.
Sizable Debt And Modest ReturnsAlthough leverage has improved, the absolute debt balance remains material and current returns on equity are only mid-single-digit. This combination suggests capital is not yet generating strong shareholder returns and leaves some balance-sheet exposure.
Dr. Agarwal's Health Care Ltd. News
AGARWALEYE FAQ
What was Dr. Agarwal's Health Care Ltd.’s price range in the past 12 months?
Dr. Agarwal's Health Care Ltd. lowest stock price was ₹402.10 and its highest was ₹567.80 in the past 12 months.
What is Dr. Agarwal's Health Care Ltd.’s market cap?
Dr. Agarwal's Health Care Ltd.’s market cap is ₹157.97B.
When is Dr. Agarwal's Health Care Ltd.’s upcoming earnings report date?
Dr. Agarwal's Health Care Ltd.’s upcoming earnings report date is Oct 29, 2026 which is in 62 days.
How were Dr. Agarwal's Health Care Ltd.’s earnings last quarter?
Currently, no data Available
Is Dr. Agarwal's Health Care Ltd. overvalued?
According to Wall Street analysts Dr. Agarwal's Health Care Ltd.’s price is currently Overvalued.
Does Dr. Agarwal's Health Care Ltd. pay dividends?
Dr. Agarwal's Health Care Ltd. does not currently pay dividends.
What is Dr. Agarwal's Health Care Ltd.’s EPS estimate?
Dr. Agarwal's Health Care Ltd.’s EPS estimate is 1.3.
How many shares outstanding does Dr. Agarwal's Health Care Ltd. have?
Dr. Agarwal's Health Care Ltd. has 317,026,180 shares outstanding.
What happened to Dr. Agarwal's Health Care Ltd.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Dr. Agarwal's Health Care Ltd.?
Currently, no hedge funds are holding shares in IN:AGARWALEYE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Dr. Agarwal's Health Care Ltd.
Dr. Agarwal's Health Care Limited manages a chain of eye hospitals both within India and abroad. The company delivers a comprehensive range of ophthalmic services, including advanced surgical solutions for cataracts like small incision, phacoemulsification, robotic, and glued intraocular lens procedures. It also offers refractive surgeries designed to correct visual errors, thereby lessening or removing the necessity for glasses and contact lenses. Additional surgical specialties include treatments for retinal conditions, corneal transplantation, pinhole pupilloplasty, oculoplasty, and operations for glaucoma and pterygium. Beyond surgical interventions, the company provides professional medical consultations, in-depth diagnostic services for various eye disorders, and non-surgical therapies such as retinal laser treatment and dry eye management. Furthermore, Dr. Agarwal's Health Care Limited sells optical goods, including spectacles, lenses, contact lenses, and frames, as well as a variety of pharmaceutical products for eye care. The company was founded in 2010 and is based in Chennai, India.
Technical Analysis
Apollo Hospitals Enterprise Limited
―
Fortis Healthcare Ltd.
―
Lotus Eye Hospital And Institute Ltd
―
Max Healthcare Institute Ltd
―
Global Health Limited
―